Astellas Pharma 

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, encompassing the development, manufacturing, distribution, and commercialization of medicinal products across international markets. Its diverse portfolio features prominent therapies such as XTANDI, an androgen receptor signaling inhibitor for prostate cancer, and XOSPATA, an FLT3 inhibitor targeting relapsed or refractory acute myeloid leukemia in adult patients with a specific FLT3 mutation. Other key offerings include PADCEV, designed for locally advanced or metastatic urothelial cancer, and the Betanis/Myrbetriq/BETMIGA family of beta-3 adrenergic receptor agonists used to alleviate symptoms of overactive bladder, including urgency, frequent urination, and urge incontinence. The company also markets Evrenzo, an oral medication for anemia linked to chronic kidney disease, and the immunosuppressants Prograf and Advagraf/Graceptor/ASTAGRAF, critical for preventing organ rejection post-transplantation. Further contributions to its product range include mirabegron for neurogenic detrusor overactivity in children, Vesicare for general overactive bladder treatment, Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, and the antifungal agent Funguard/MYCAMINE. Astellas is actively engaged in numerous strategic alliances and collaborations to advance its research and development initiatives. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an agreement with BANDAI NAMCO Entertainment Inc. for a smartphone-based exercise support application. The company maintains a strategic research alliance with Harvard University, focusing on the co-development of novel therapeutics and technologies. Additionally, it has a research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies utilizing Actinium's Antibody Warhead Enabling technology platform, and an agreement with Zenith Epigenetics Ltd. to assess ZEN-3694. A collaboration agreement is also in place with Cytokinetics, Incorporated. Furthermore, Astellas has a strategic collaboration and licensing deal with Minovia Therapeutics Ltd. aimed at the research, development, and commercialization of cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Established in 1923, Astellas Pharma Inc. has its corporate headquarters situated in Tokyo, Japan.